News Column

Recent Findings by Z.X. Lu and Colleagues in Myocardial Infarction Provides New Insights

June 2, 2014

By a News Reporter-Staff News Editor at Cardiovascular Week -- Current study results on Heart Diseases and Conditions have been published. According to news reporting from Shanghai, People's Republic of China, by NewsRx journalists, research stated, "To comparatively evaluate the cardioprotective activity of placental growth factor (PGF) delivered through direct injection and a nanoparticle-based system respectively and to study the underlying mechanisms in a rat model of acute myocardial infarction (AMI). Poly lactic-co-glycolic acid (PLGA)-based PGF-carrying nanoparticles (PGF-PLGA(NPs)) were created."

The news correspondents obtained a quote from the research, "The mean size and morphology of particles were analyzed with particle size analyzer and transmission electronic microscopy (TEM). Encapsulation efficiency and sustained-release dose curve were analyzed by ELISA. Sprague-Dawley rats were randomized into four groups (n = 10). While animals in the first group were left untreated as controls, those in the other 3 groups underwent surgical induction of AMI, followed by treatment with physiological saline, PGF, and PGF-PLGA(NPs), respectively. Cardiac function was evaluated by transthoracic echocardiography at 4 weeks after treatment. At 6 weeks, rats were sacrificed, infarction size was analyzed with Masson trichrome staining, and protein contents of TIMP-2, MT1-MMP and MMP-2 at the infarction border were determined by immunohistochemistry and western blotting analysis. PGF was released for at least 15 days, showing successful preparation of PGF-PLGA(NPs). Coronary artery ligation successfully induced AMI. Compared to physiological saline control, PGF, injected to the myocardium either as a nude molecule or in a form of nanoparticles, significantly reduced infarction size, improved cardiac function, and elevated myocardial expression of TIMP-2, MT1-MMP, and MMP-2 (P < 0.05). The effect of PGF-PLGA(NPs) was more pronounced than that of non-encapsulated PGF (P < 0.05). Target PGF delivery to myocardium may improve cardiac function after AMI in rats. PLGA-based nanoparticles appear to be a better approach to delivery PGF."

According to the news reporters, the research concluded: "PGF exerts its cardioprotective effect at least partially through regulating metalloproteinase-mediated myocardial tissue remodeling."

For more information on this research see: Cardioprotective activity of placental growth factor in a rat model of acute myocardial infarction: nanoparticle-based delivery versus direct myocardial injection. BMC Cardiovascular Disorders, 2014;14():1-9. BMC Cardiovascular Disorders can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central -; BMC Cardiovascular Disorders -

Our news journalists report that additional information may be obtained by contacting Z.X. Lu, China State Inst Pharmaceut Ind, Natl Pharmaceut Engn Res Center, Shanghai 200437, People's Republic of China. Additional authors for this research include L.L. Mao, F. Lian, J. He, W.T. Zhang, C.Y. Dai, S. Xue, W.G. Lu and H.S. Zhu (see also Heart Diseases and Conditions).

Keywords for this news article include: Asia, Shanghai, Cardiology, Heart Attack, Nanoparticle, Nanotechnology, Vascular Diseases, Myocardial Ischemia, Emerging Technologies, People's Republic of China, Acute Myocardial Infarction, Heart Diseases and Conditions

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cardiovascular Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters